LYRA - Lyra Therapeutics resumes enrollment for second part of Phase 3 trial of chronic rhinosinusitis treatment

2023-04-25 08:55:36 ET

• Lyra Therapeutics ( NASDAQ: LYRA ) said it had resumed screening and enrollment for its second Phase 3 clinical trial of LYR-210 to treat chronic rhinosinusitis (CRS).
• LYR-210 is a bioresorbable nasal implant and acts as an alternative to sinus surgery for patients who remain symptomatic despite treatment.
• Lyra announced in November that it had temporarily paused enrollment in the second trial, ENLIGHTEN II, due to a transition to in-house manufacturing to ensure consistent clinical supply of LYR-210.
• The company expects to complete enrollment in the second trial in H2 2024. Lyra is manufacturing LYR-210 in house for both ENLIGHTEN trials.
• The program consists of two Phase 3 trials - ENLIGHTEN I and ENLIGHTEN II - to evaluate the efficacy and safety of LYR-210 for the treatment of CRS.
• The company said patient enrollment in the ENLIGHTEN I trial remains on track, with pivotal data anticipated in 1H 2024.
• (( LYRA ) is up ~2% premarket.
• Press Release

For further details see: